EN | UA
EN | UA

Help Support

Back

Higher level of CAR is related to worse 5-year outcomes among diabetic patients with PCI

Type 2 diabetes Type 2 diabetes
Type 2 diabetes Type 2 diabetes

What's new?

A new inflammatory biomarker, hs-CRP-to-albumin ratio, is linked with worse five-year outcomes in people with type 2 diabetes who undergo PCI.

In a recent study, diabetic people undergoing percutaneous coronary intervention (PCI) had worse 5-year outcomes when their high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) levels were higher. Individuals suffering from coronary artery disease combined with diabetes are at a greater risk of cardiovascular events. CAR is a new inflammatory biomarker. But, whether CAR can recognize high-risk people suffering from type 2 diabetes mellitus (T2DM) and coronary artery disease is not clear.

This real-world cohort study was based on an observational and prospective cohort encompassing 10,724 volunteers who were scheduled to undergo PCI with dual antiplatelet therapy. All-cause mortality was the key endpoint while cardiac mortality served as the secondary endpoint. Using the formula: hs-CRP (mg/L)/albumin (g/L), CAR was computed. Volunteers were separated into higher CAR (CAR-L) and lower CAR (CAR-L) groups based on the ideal CAR cut-off value for all-cause death.

Final enrollment included 2755 T2DM people who had PCI and received dual antiplatelet treatment. A 5-year follow-up (interquartile range: 5.0–5.1 years) revealed 126 (4.6%) all-cause fatalities and 74 (2.7%) cardiac fatalities. CAR-H was linked to an escalated risk of all-cause death (hazard ratio [HR]: 1.634) and cardiac mortality (HR: 1.733) in comparison with CAR-L in the multivariable Cox model.

CAR outperformed hs-CRP in terms of predictive value for both cardiac mortality (area under the curve [AUC] 0.602 vs. 0.593) and all-cause mortality (AUC 0.588 vs. 0.580). Hence, individuals with T2DM treated with PCI who have raised CAR levels experience more risk of long-term mortality (cardiac and all-cause mortality) than those with reduced levels of CAR.

Source:

Diabetology & Metabolic Syndrome

Article:

A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention

Authors:

Jiawen Li et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: